23 results on '"Tuffy, Kevin M."'
Search Results
2. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
3. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
4. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
5. Serum AZD7442 (tixagevimab–cilgavimab) concentrations and in vitroIC50 values predict SARS‐CoV‐2 neutralising antibody titres.
6. 2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
7. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
8. Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
9. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
10. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
11. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data
12. 94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants
13. 1110. AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies
14. Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring
15. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
16. Validation and performance of a multiplex serology assay to quantify antibody responses following SARS‐CoV‐2 infection or vaccination
17. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
18. AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
19. HIV-1 Gag Forms Ribonucleoprotein Complexes with Unspliced Viral RNA at Transcription Sites
20. Visualizing Association of the Retroviral Gag Protein with Unspliced Viral RNA in the Nucleus
21. Cytoskeleton-Associated Protein 4: Functions Beyond the Endoplasmic Reticulum in Physiology and Disease
22. Influenza A and B Virus Intertypic Reassortment through Compatible Viral Packaging Signals
23. Serum AZD7442 (tixagevimab-cilgavimab) concentrations and in vitro IC 50 values predict SARS-CoV-2 neutralising antibody titres.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.